Celgene and Novartis to develop SERMs

CELG and Novartis (NVS; SWX:NOVN) will develop selective estrogen receptor modulators (SERMs) to prevent or treat osteoporosis. CELG said it has a series of SERM-alpha compounds that have a novel core...